Human Influenza

26 registered clinical trials studyying Human Influenza — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Completed	Universal Influenza A Vaccine in Healthy Adults NCT05155319	Emergent BioSolutions	Phase 1
Recruiting	Tfh Dysfunction in HIV and Aging NCT04487041	University of Miami	Phase 4
Terminated	Evaluation of a Single Use Point of Care Device for the Diagnosis of Respiratory Pathogens NCT04431050	Imperial College London	—
Completed	Safety of 4Fluart ID Suspension for Injection in Adult Subjects NCT03448705	Fluart Innovative Vaccine Ltd, Hungary	Phase 1
Completed	Preventive Effectiveness, Safety and Immunogenicity of a Allantoic Split Inactivated Seasonal Influenza Vaccin NCT03572491	Research Institute for Biological Safety Problems	Phase 3
Completed	Transmission of Influenza Virus From Asymptomatic Healthcare Workers and Inpatients in the Acute Care Hospital NCT02478905	University of Zurich	—
Completed	Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in A NCT02600585	Protein Sciences Corporation	—
Completed	A Study to Evaluate Safety and Immunogenicity of Trivalent Influenza Vaccine, Formulation 2015 Southern Hemisp NCT02427750	Novartis	Phase 2
Completed	Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection for Children and Adolescents NCT02387294	Fluart Innovative Vaccine Ltd, Hungary	Phase 3
Completed	Clinical Trial for the Evaluation of Three Regimens of Influenza Vaccination in Kidney Transplant Recipients NCT02104869	Butantan Institute	Phase 4
Completed	Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvanted Influenza Study Vaccine in Adults NCT01880697	Novartis Vaccines	Phase 3
Completed	Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface An NCT01885117	Novartis Vaccines	Phase 3
Completed	Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, NCT01879540	Novartis Vaccines	Phase 2
Completed	Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, NCT01879553	Novartis Vaccines	Phase 2
Terminated	Panama and El Salvador Children's Oseltamivir Study NCT01690637	Centers for Disease Control and Prevention	Phase 4
Completed	Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects NCT01651104	Novartis Vaccines	Phase 2
Completed	Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years NCT01636102	Novartis Vaccines	Phase 2
Completed	Phase IV Clinical Trial of an Inactivated Influenza Split Vaccine NCT01511744	Hualan Biological Engineering, Inc.	Phase 4
Completed	Conventional Vaccine and Intradermal Vaccine Among HIV-infected Young Subjects NCT02398097	Korea University Guro Hospital	Phase 4
Completed	Study of Yili Mei Yi Tian Active Lactobacillus Drink to Improve Immunity and Digestive System NCT01677715	Inner Mongolia Yili Industrial Group Co., Ltd	N/A
Completed	Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventiona NCT01342796	Novartis Vaccines	Phase 2
Completed	Study of Yili Lactoferrin ShuHua Milk in the Improvement of Human Immunization NCT01677702	Inner Mongolia Yili Industrial Group Co., Ltd	N/A
Unknown	Immunogenicity Study of S-OIV H1N1 Influenza Vaccine NCT01096225	Chinese Academy of Sciences	—
Completed	Bangladesh Secondary Transmission Handwashing Protocol NCT00880659	International Centre for Diarrhoeal Disease Research, Bangladesh	Phase 2
Completed	Efficacy and Safety of Enisamium Iodide for the Treatment of Acute Respiratory Viral Infections, Including Inf NCT04682444	Joint Stock Company "Farmak"	Phase 2 / Phase 3
Completed	Post-marketing Clinical Observation of an Inactivated Influenza Split Vaccine NCT01568788	Hualan Biological Engineering, Inc.	N/A